Better Buy for Cautious Investors: Eli Lilly vs Costco
The article compares Eli Lilly and Costco as defensive stock picks for cautious investors amid market hesitation. Eli Lilly benefits from its dominant GLP-1 weight loss drug portfolio (Mounjaro and Zepbound), while Costco offers stability through its membership-based business model with high renewal rates. Despite both stocks being reasonably valued, the author recommends Costco as the better buy, trading at approximately 39x forward earnings compared to Eli Lilly's historical valuation levels.